| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
DOPE-PEG-Mal does not have a classical pharmacological target but functions as a drug delivery excipient. The DOPE moiety anchors the molecule into lipid bilayers, the PEG spacer provides water solubility and stealth properties, and the maleimide group enables conjugation to thiol-containing molecules.
|
|---|---|
| ln Vitro |
In vitro, DOPE-PEG-Mal is used to formulate liposomes and other lipid-based nanoparticles for drug delivery. The PEG spacer improves circulation time and stability of encapsulated drugs. The maleimide group enables conjugation to thiol-containing targeting ligands such as antibodies or peptides for targeted drug delivery.
|
| ln Vivo |
In vivo, DOPE-PEG-Mal is used in drug delivery formulations to improve therapeutic outcomes. Pegylation of phospholipids significantly improves the blood circulation time and stability for encapsulated drugs. Surface modification with targeting ligands enables targeted drug delivery.
|
| Enzyme Assay |
The non-cellular assay for DOPE-PEG-Mal involves characterizing its chemical properties. Key analytical techniques include HPLC, NMR, and mass spectrometry to confirm structure, purity, and PEG molecular weight. Liposome formation and stability can be assessed using dynamic light scattering and electron microscopy.
|
| Cell Assay |
In vitro cell-based assays for DOPE-PEG-Mal involve incorporating the lipid into liposomes or nanoparticles and testing their uptake and efficacy in cell culture models. Cells are treated with drug-loaded formulations, and cellular uptake is assessed by fluorescence microscopy or flow cytometry. Cytotoxicity and efficacy are evaluated using standard cell viability assays.
|
| Animal Protocol |
In vivo animal study protocols for DOPE-PEG-Mal involve administering drug-loaded liposomes or nanoparticles to animal models. The PEGylated lipid improves circulation time and stability. Endpoints include pharmacokinetics, biodistribution, and therapeutic efficacy. Standard protocols for drug delivery studies are followed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DOPE-PEG-Mal are determined by its formulation properties. The PEG spacer of MW 3400 provides extended circulation time. When incorporated into liposomes, the lipid contributes to the overall pharmacokinetic profile of the delivery system. The maleimide group enables conjugation for targeted delivery.
|
| Toxicity/Toxicokinetics |
Toxicological data for DOPE-PEG-Mal are limited. As a phospholipid, it is generally considered biocompatible. Standard safety precautions should be observed during handling. The product is for research use only.
|
| References | |
| Additional Infomation |
DOPE-PEG-Mal (MW 3400) is a phospholipid used as an excipient in drug formulations. It has good biocompatibility and amphiphilic characteristics. The maleimide group enables conjugation to thiol-containing molecules for targeted delivery. It is not a therapeutic drug.
|
| Molecular Weight |
3400 (Average)
|
|---|---|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
